Granules India posts Q1 FY25 consolidated PAT higher at Rs. 134.64 Cr
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
These gummies are specially formulated for both kids and adults to nourish the eyes and promote optimal vision development
Decision on EU marketing authorisation for this population expected by September 2024
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
GSK and Flagship to jointly fund up to $150 million upfront
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
Report highlights significant improvements in adolescent well-being in India
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated